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Abstract-—6-Methylmereaptopurine ribonucleoside-5'-phosphate (MeSPuRMP), the sole metabolite of 
6-methylmercaptopurine ribonucleoside (MeSPuRib), is a strong inhibitor of purine de novo  synthesis, 
inducing depletion of intracellular purine nucleotides and subsequent cell death in several tumor cell 
lines. In this study prevention of MeSPuRib cytotoxicity by compounds of the purine salvage pathway 
was studied in Molt F4 human malignant T-lymphoblasts. Adenosine, adenine and inosine were able 
to prevent depletion of the adenine nucleotide pool when used in combination with 0.5 (M  MeSPuRib, 
but had virtually no effect on depletion of guanine nucleotides. Nevertheless, these three purine 
compounds were able to reduce the cytotoxic effects induced by MeSPuRib. Addition of guanosine to 
cells treated with 0 .5 /¿M MeSPuRib normalized the guanine nucleotide pool, but adenine nucleotides 
remained depleted. Under these conditions, inhibition of cell growth was significantly decreased. With 
the combination of guanosine and IOjwM MeSPuRib, cytotoxicity was increased compared to 10 fiM 
MeSPuRib alone, associated with a depletion of adenine nucleotides to 9%  of untreated cells. Since 
cell growth and cell viability of Molt F4 cells are less inhibited by MeSPuRib under conditions where 
adenine nucleotide depletion is prevented by purine compounds (and where the other nucleotides are 
depleted) we conclude that depletion of adenine nucleotides is an important factor in MeSPuRib
•  %cytotoxicity.
MeSPuRib,f an adenosine antimetabolite, is cyto- anticancer activity of orally administered 6-MP [19]. 
toxic for a number of cell lines, and exhibits some The metabolic route by which 6-MP is generally
anticancer activity in vivo [1-5]. MeSPuRib thought to induce cytotoxicity is conversion into 6-
•  a  «  a * «  •  4 *
cytotoxicity is by its met< thioguanine ides, and subse
MeSPuRMP, which is formed from MeSPuRib by poration into DNA and RNA [19, 20]. Furthermore,
adenosine kinase (Scheme 1) [3,6-8]. MeSPuRMP a high activity of thiopurine methyltransferase in
is a strong inhibitor of purine de novo synthesis [ 9, 10] red blood cells, resulting in MeSPuRMF
at PRPP amidotransferase [9, 11-13). Inhibition ot concentrations, correlates with a poor prognosis in
this route induces a depletion of purine nucleotides children receiving oral 6-MP therapy, suggesting that
[4, 5, 14—16], thereby leading to diminution ot RNA t jie méthylation route of 6-MP is a catabolic pathway
and DNA formation [14], and subsequent inhibition [ n ,  ir ]. Our studies of Molt F4 cells, a human 
of cell growth and loss ot cell viability (3-5, 15]. ......  ..... lymphoblastic cell line, indicated that
MeSPuRMP is also an important metabolite of under conditions where intracellular MeSPuRMP
the anticancer agent 6-MP. 6-MP is hnrt conveitet concentrations were elevated, cytotoxicity of 6- 
mto SIMP and the lattei into MeSPuRM by was increased [21]. Furthermore, cytotoxicity of
both 6-MP and MeSPuRib could be reversed inrine met
it [17-19]. 6-MP is 
commonly used in the oral maintenance treatment 
of children with acute lymphoblastic leukemia 
17, 18]. At present it is under discussion whether
cells by addition of amidoimidazolecarboxamide
j com is
formation to
" m t m
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t  Abbreviations: MeSPuRMP, 6-methylmercaptopurine 
ribonucleoside-5'-phosphate; MeSPuRib, 6-
captopurine ribonucleoside; PRPP, phosphoribosyl- 
pyrophosphate; SIMP, 6-thioinosine 5' monophosphate; 
6-MP, 6 mercaptopurine; AICAR, amidoimidazole-
AICAR, which is an intermediate of purine de novo 
synthesis distal to the MeSPuRMP inhibition site 
[22], providing further evidence for the cytotoxic
MeSPuRMP in
sd that the cytotoxic effect 
of MeSPuRMP in these cells is the first step in the 
purine biosynthetic pathway.
In the present study we obtained more evidence 
regarding MeSPuRMP cytotoxicity in Molt F4 human 
T-lymphoblasts. To determine whether MeSPuRib 
cytotoxicity could be prevented by purine inter-
carboxamide ribonucleotide; PC A, perchloric acid; IMP, mediates of the purine salvage route (Scheme 1)
inosine 5' monophosphate. cell growth, cell viability, endogenous nucleotide
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Scheme 1. Purine salvage pathway. 1, Adenosine kinase; 2, hypoxanthine guanine phos- 
phoribosyltransferase; 3, adenine phosphoribosyltransferase; 4, 5' nucleotidase; 5, purine nucleoside
phosphorylase; 6, phosphoribosylpyrophosphate amidotransferase; 7, PRPP synthetase.
concentrations, extracellular nucleosides and bases, U.S.A.), and were detected at a wavelength of 
and formation of MeSPuRMP were determined in 254 nm. Concentrations were expressed as /«nol/L.
experiments where cells were treated with various 
concentrations of MeSPuRib alone, and in com­
bination with adenosine, adenine, inosine or 
guanosine.
RESULTS
MATERIALS AND METHODS
Treatment of Molt F4 cells with 0.5 fiM MeSPuRib 
resulted in decreased purine nucleotide con­
centrations (Table 1) and led to inhibition of cell 
growth and of cell viability (Fig. 1). The effects of 
10 ,uM MeSPuRib on these parameters were similar
MeSPuRib, adenosine, adenine, inosine and (Table 2 and Fig. 2).
guanosine were obtained from Sigma Chemicals Addition of 50 ^M adenosine or adenine, or 25 [iM
(St Louis, MO, U.S.A.). The experiments were inosine in combination with 0.5 /iM MeSPuRib
performed with Molt F4 cells, a T-cell acute prevented the reduction of the intracellular adenine
lymphoblastic leukemia cell line. Conditions for cell nucleotide pool by MeSPuRib within the first 24 hr
culture and experimental procedures have been of treatment (Table 1). Adenosine was also able to
described earlier [21]. MeSPuRib and adenosine, restore the guanine nucleotide pool after 24 hr.
adenine, inosine, guanosine or combinations of Adenine and inosine hardly affected the depletion
MeSPuRib with one of these purine compounds of guanine nucleotides (Table 1). These purine
were added as a single dose in a small volume compounds were able to prevent inhibition of cell
growth partially and cell viability nearly completely
Intracellular nucleotides (di- and triphosphates) (Fig. 1). Combination of these purine compounds
and MeSPuRMP were extracted from 3 x 106 viable with 10 piM MeSPuRib partly prevented depletion
means of perchloric acid (PCA, BDH of the adenine nucleotide pool, especially at 24 hr,
Chemicals Ltd, Poole, U.K.) as described earlier but did not prevent the depletion of the guanine
[21] and analysed by means of HPLC at a wavelength nucleotide pool (Table 2). Cytotoxicity was decreased
of 254 nm and 240 nm, respectively [231. The 
concentrations were expressed as pmoles/lO" viable
as a result of addition of these purine compounds to 
treatment with 10 pM  MeSPuRib (Fig. 2).
Addition of 25 ptM guanosine to treatment with 
Extracellular nucleosides and bases were extracted 0.5 MeSPuRib resulted in an increase of the 
from 0.5 mL of the culture medium (after the cells intracellular guanine nucleotide pool, but had no 
had been removed), to which a volume of 25 juL 8 M effect on the reduction of the adenine nucleotide 
PCA was added. This was kept on ice for lOmin. pool (Table 1). If anything, the reduction of the 
Then the samples were centrifuged for 2 min, after adenine nucleotide pool became more severe, 
which the supernatant was neutralized with 4M Furthermore, this combination resulted in almost 
K2HPO4. Nucleosides and bases were determined normal cell viability (Fig. lb), and cell growth was 
by means of reversed-phase HPLC, with a Supelcosil only partly affected (Fig. la). In contrast, guanosine 
LC-18-DB column (25 cm X 4.6 mm, Supelco, in combination with 10 juM MeSPuRib led to a large
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Fig. 1. Cell growth (a) and cell viability (b) of Molt F4 
cells after treatment with 0.5 juM MeSPuRib alone or in 
combination with 50 fiM adenosine, 50 ^M adenine, 25 ¿<M 
inosine or 25 ¡uM guanosine, The results of one experiment 
are shown. Similar results were obtained in two other
experiments.
increase of cytotoxicity as compared to 10 //.M 
MeSPuRib alone (Fig. 2). Under these conditions 
intracellular adenine nucleotides were depleted to 
9% of untreated cells after 24 hr (Table 2).
To gain an insight into the metabolic fate of the 
purine compounds after addition to the cells alone, 
or in combination with MeSPuRib, concentrations of 
extracellular nucleosides and bases were determined. 
The results of these experiments are shown in Table 
3. Adenosine can be incorporated via two pathways: 
directly by adenosine kinase and indirectly by 
conversion into inosine, which is then converted into 
hypoxanthine, and subsequently into IMP (Scheme 
1). The operation of this second route was reflected
by extracellular inosine and
hypoxanthine after addition of 50 /uM adenosine to 
Molt F4 cells (Table 3). No extracellular adenosine
. When inosine is used, it 
catabolized to hypoxanthine, which is subsequ 
phosphorylated by hypoxanthine 
phoribosyltransferase to IMP. Both 
hypoxanthine were detectable in the medium for the 
first 6 hr after the start of the experiment (Table
3). Adenine is meti by adenine
phosphoribosyltransferase to adenine S'-mono- 
phosphate (AMP), and is present in the medium 
until 48 hr (Table 3). After addition of guanosine
and guanine are present 
(Table 3). In general the disappearance of the added
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Fig. 2. Cell growth (a) and cell viability (b) of Molt F4 
cells after treatment with 10 jitM MeSPuRib alone or in 
combination with 50 /tM adenosine, 50 /iM adenine, 25 /iM 
inosine or 25 /iM guanosine. The results of one experiment 
are shown. Similar results were obtained in two other
purine compounds from the medium was slower
when m c ation 1 0  / t M
MeSPuRMF concentrations were determined to
evaluate the of bases and
nucleosides on MeSPuRib metabolism. Combination 
of 0.5 juM MeSPuRib with the purine compounds 
resulted in a decrease of MeSPuRMP concentrations 
after 48 hr (Fig. 3a). With lO^uM
addition of adenosine, adenine and inosine resulted
concentration.in a in
aHowever, addition of guanosine 
MeSPuRMP concentration after 48 hr as compared 
to 10 uM ib alone (Fig. 3b).
j c u s r
activity after conversion to MeSPuRMP, a strong 
inhibitor of purine de novo synthesis [9,10). In this 
study the effects of MeSPuRib on Molt F4 human 
T-lymphoblasts have been determined. Inhibition of 
cell growth, cell viability and purine 
concentrations (Fig. 1, Table 1) are already maximal 
with 0.5 (M  MeSPuRib [24]. With 10 /¿M MeSPuRib 
no additional effects on cytotoxicity and on purine 
nucleotide pools are observed (Fig. 2 , Table 2). 
Because Molt F4 cells have a highly active purine
Reversal of 6-methylmercaptopurine ribonucleoside cytotoxicity 
Table 3. Medium concentrations of purine nucleosides and bases, expressed in /«nol/1.
Time (hr) Hypoxanthine Adenine Inosine Guanosine Guanine
Control 2 0.39 ND ND ND ND
6 0.31 ND ND ND ND
24 0.34 ND ND ND ND
48 0.49 ND ND ND ND
0 . 5 fiM 2 0.37 ND ND ND ND
MeSPuRib 6 0.33 ND ND ND ND
24 0.40 ND ND ND ND
48 0.46 ND ND ND ND
10 /uM 2 0.36 ND ND ND ND
MeSPuRib 6 0.37 ND ND ND ND
24 0.48 ND ND ND ND
48 0.46 ND ND ND ND
50 /¿M 2 33.17 ND 13.01 ND ND
adenosine 6 34.54 N D 4.93 ND ND
24 16.03 ND ND ND ND
48 0.42 ND ND ND ND
50 jt/M 2 0.67 45.6 ND ND ND
adenine 6 0.61 35.11 ND ND ND
24 0.58 15.59 ND ND ND
48 0.44 ND ND ND ND
25 jtiM 7 18.94 ND 9.62 ND ND
inosine 6 15.75 ND 1.53 ND ND
24 0.53 ND ND ND ND
48 0.41 ND ND ND ND
25 ^M 2 ND ND ND 5.40 16.52
guanosine 6 ND ND ND 2.45 20.09
24 0.43 ND ND ND ND
48 0.37 ND ND ND ND
0.5 ¿iM 2 25.29 ND 14.10 ND ND
MeSPuRib 6 31.84 ND 4.07 ND ND
+  adenosine 24 19.33 ND ND ND ND
48 0.40 ND ND ND ND
0.5 ,uM 2 0.71 37.36 ND ND ND
MeSPuRib 6 0.67 36.32 ND ND ND
+ adenine 24 0.68 20.15 ND ND ND
48 0.41 ND ND ND ND
0.5 /¿M im u* 16.43 ND 2.91 ND ND
MeSPuRib 6 16.42 ND 1.06 ND ND
+ inosine 24 2.45 ND ND ND N D
48 0 . 42 ND ND ND ND
0.5 //M 2 ND ND ND 3.50 13.92
MeSPuRib 6 ND ND ND 1.40 it  r*A *  1  1  A *  v '
+ guanosine 24 ND ND ND ND 6.68
48 0.39 ND ND ND ND
10 /<M 2 26.81 ND 17.59 ND N D
MeSPuRib 6 34.95 ND 3.35 ND ND
+ adenosine 24 29.56 ND ND ND ND
48 13.72 ND ND ND ND
10//M 2 0.85 39.93 ND ND ND
MeSPuRib 6 0.84 38.97 ND N D ND
+ adenine 24 1.10 36.29 ND ND ND
48 1.27 14.06 ND ND ND
10 //M 2 15.42 ND 3.28 N D ND
MeSPuRib 6 16.65 N D 0.60 ND N D
+ inosine 24 8.88 ND ND ND ND
48 0.5 6 ND ND N D ND
10 } M 2 ND ND ND 4.96 18.04
MeSPuRib 6 ND ND ND 1.99 21.93
+ guanosine 24 ND ND ND 0.36 18.54
48 ND ND ND 0.47 23.09
Data from one representative experiment are shown (ND, not detectable).
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Fig. 3. MeSPuRMP concentrations of Molt F4 cells treated with either 0.5 ¿¿M (a) or 10 /tM (b) 
MeSPuRib alone or in combination with the purine salvage intermediates described in Fig. 1 (expressed
as pmoles/106 viable cells; mean with standard error of three independent experiments).
de novo synthesis [25], these cells are highly observed earlier in HL-60 cells [15] and in sarcoma 
susceptible to MeSPuRMP cytotoxicity. 180 cells [26]. With 10 piM MeSPuRib normalization
Adenosine, adenine and inosine are able to of the intracellular adenine nucleotide pool as a
prevent inhibition of purine de novo result of addition of the purine bases and nucleosides
induced by 0.5 nM MeSPuRib, leading to almost is less pronounced (Table 2). This may be attributed
normal cell growth and cell viability (Fig. 1, Table to two phenomena. First, when adenosine is used in
1). The effects of these three purine compounds on combination with a high concentration of MeSPuRib,
purine nucleotide concentrations are comparable. competition for adenosine kinase may occur, since
The initial normalization during the first 24 hr of both adenosine and MeSPuRib are metabolized by
intracellular adenine nucleotides is followed by this enzyme (Scheme 1). As a result, less adenosine
depletion (Table 1). This is the result of the very can be phosphorylated by the cells. This process is
rapid conversion of the purine bases and nucleosides, reflected by the prolonged presence of extracellular
as determined by the rapid disappearance of these hypoxanthine (Table 3), a product of adenosine
compounds and their derivates from the incubation catabolism, which indicates a slow anabolism of
medium (Table 3). Reversal of the effects of 3 /aM adenosine under these conditions. Second, it is
MeSPuRib on induction of differentiation, cell known that a high MeSPuRMP concentration results
growth inhibition and purine nucleotide con- in inhibition of PRPP synthetase [24,27,28]. As
centrations by various concentrations of adenine was PRPP is a substrate for the enzymes adenine
Reversal of 6-methylmercaptopurine ribonucleoside cytotoxicity
phosphoribosyltransferase and hypoxanthine guan- MeSPuRib for adenosine kinase, since
ine phosphoribosyltransferase and thus is involved compounds are metabolized by this enzyme. It is at 
in the metabolism of adenine and inosine (the latter present not clear how addition of adenine, inosine 
being first converted into hypoxanthine), less adenine and MeSPuRMP ation.
and inosine will be incorporated into the cells with Perhaps these purine compounds interfere with the 
10/uM MeSPuRib. Again, this is reflected by transport of MeSPuRib, thereby •'"•‘'a s ing
the concentrations of extracellular and concentration of intracellular MeSPuRib and
hypoxanthine after treatment with 10 /¿M MeSPuRib MeSPuRMP.
in combination with either inosine or adenine (Table In conclusion, depletion of intracellular adenine
3). nucleotide concentration appears an important factor
The minor effects of adenine, adenosine and in MeSPuRib cytotoxicity. This is in contrast with
inosine on the intracellular guanine nucleotide pool earlier observations that the biological consequences
caused by 0.5 jUM and 10 ¿iM MeSPuRib (Tables 1 of purine starvation as a r
and 2) are probably the result of a preferential treatment were primarily due to guanine nucleotide
* V  T i  \ concentration. >n in a mouse T-
Moreover, conversion of bases and nucleosides into a result of addition of adenosine, adenine and 
guanine nucleotides is a much slower process than to treatment with MeSPuRib, the adenine nuc 
conversion into adenine nucleotides [29]. were restored to nearly normal values
The severe cytotoxicity observed with the first 24 hr of treatment, whereas guanine nucleotides 
combination of lO^uM MeSPuRib and 2 5 /iM remained depleted (Tables 1 and 2), and
nucleotides (data not shown) became deple
it consumption of
î ascribed to a nearly is a
purine
 ft
guanosine (Fig. 2) can t
complete reduction in intracellular adenine nucleo­
tides, which is induced by several mechanisms. First, salvage intermediates. Since cell growth and cell
inhibition of purine de novo  synthesis by MeSPuRib viability of Molt F4 cells still partly recovered to
will result in a depletion of adenine nucleotides, control values under these conditions, restoration of 
Second, MeSPuRib is converted into MeSPuRMP the depletion of adenine nucleotides is also important 
by the enzyme adenosine kinase, a reaction which for amelioration of the effects of inhibition of purine 
consumes ATP and thus induces a further decrease de novo  synthesis by MeSPuRib.
Furthermore, it appears of importance to use at 
least two concentrations of MeSPuRib to study the 
effects of purine salvage intermediates on MeSPuRib 
48 hr (Table 2). The formation of GDP and GTP induced cytotoxicity, since this reveals more of the 
from GMP consumes ATP by kinase reactions, underlying mechanisms of cytotoxicity.
of adenine nucleotide concentrations. Third, addition 
of guanosine leads to an increase in guanine 
nucleotides 2.5 times that of the control value at
Therefore the adenine nucleotide will
d e p le te d  fu r th e r ,  lead ing  to  the  d ra m a tic  red u c tio n  Acknowledgement—This study was funded by the Dutch 
in in trace llu la r  ad en in e  n u c le o tid e s  o b se rv ed  in these  Cancer Society, Grant NUKC 89-13.
experiments. Combination of guanosine with 0.5 /¿M 
MeSPuRib does not induce such a severe depletion
of 1), since at
concentration of MeSPuRib less ATP is consumed
a of kinase
mediated conversion of MeSPuRib into MeSPuRMP.
Exacerbation of b v
guanosine was reported earlier [15, 30,31], and was 
explained by these authors as a synergistic action 
between GMP and MeSPuRMP, resulting in a more 
severe inhibition of 
presumably at PRPP amidotransferase [30]. The 
results of our study do not confirm this conclusion, 
since the guanine nucleotide pools are also elevated
novo  s
with the ation of 0.5
guanosine, which does not lead to a more severe 
depletion of adenine nucleotides as compared to
0.5 /.iM MeSPuRib alone (Table 1). Rather the more
the combination of 10 ¿uM MeSPuRib and guanosine 
is the result of the severe depletion of the adenine 
nucleotide pool observed under these conditions. 
Since the conversion of ribose-5'-phosphate to PRPP 
is ATP dependent, severe depletion of ATP may 
lead to less availability of PRPP for purine de novo  
synthesis [24).
The decrease in MeSPuRMP concentrations as a 
result of addition of adenosine as 
treatment with MeSPuRib alone (Fig. 2) may be the
to
result of competition idenosine and
1
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